IMOVAX DT Israel - English - Ministry of Health

imovax dt

sanofi israel ltd - aluminium hydroxide; diphtheria toxoid; tetanus toxoid - suspension for injection - diphtheria toxoid 2 iu / 0.5 ml; tetanus toxoid 20 iu / 0.5 ml; aluminium hydroxide 0.6 mg / 0.5 ml - tetanus toxoid, combinations with diphtheria toxoid - tetanus toxoid, combinations with diphtheria toxoid - this vaccine is indicated for adults over 18 years of age in the following cases:- routine booster vaccinations against diphtheria and tetanus. the diphtheria toxoid content is reduced to one tenth of the normal dose to minimize the risks of a severe hypersensitivity reaction.- primary vaccination.- post-exposure prophylaxis following a tetanus-prone wound, if a booster diphtheria injection is required.this adsorbed diphtheria and tetanus vaccine may be administered as a booster vaccination in children over 10 years of age in whom poliomyelitis is prevented by separate administration of poliomyelitis vaccine.

ADT BOOSTER diphtheria and tetanus vaccine, adsorbed suspension for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

adt booster diphtheria and tetanus vaccine, adsorbed suspension for injection vial

seqirus pty ltd - tetanus toxoid, quantity: 40 iu/ml; diphtheria toxoid, quantity: 4 iu/ml - injection, suspension - excipient ingredients: water for injections; sodium chloride; aluminium hydroxide hydrate; sodium hydroxide - vaccination of children (greater than or equal to 5 years of age) and adults who have previously received at least 3 doses of a vaccine for primary immunisation against diphtheria and tetanus. adt booster is not intended for primary immunisation against diphtheria and tetanus. use of adt booster should be scheduled in accordance with official national recommendations.

ADT BOOSTER diphtheria and tetanus vaccine, adsorbed suspension for injection syringe Australia - English - Department of Health (Therapeutic Goods Administration)

adt booster diphtheria and tetanus vaccine, adsorbed suspension for injection syringe

seqirus pty ltd - diphtheria toxoid, quantity: 4 iu/ml; tetanus toxoid, quantity: 40 iu/ml - injection, suspension - excipient ingredients: water for injections; sodium hydroxide; aluminium hydroxide hydrate; sodium chloride - vaccination of children (greater than or equal to 5 years of age) and adults who have previously received at least 3 doses of a vaccine for primary immunisation against diphtheria and tetanus. adt booster is not intended for primary immunisation against diphtheria and tetanus. use of adt booster should be scheduled in accordance with official national recommendations.

INFANRIX diphtheria toxoid / pertactin / pertussis filamentous haemagglutinin / pertussis toxoid / tetanus toxoid 0.5mL injectio Australia - English - Department of Health (Therapeutic Goods Administration)

infanrix diphtheria toxoid / pertactin / pertussis filamentous haemagglutinin / pertussis toxoid / tetanus toxoid 0.5ml injectio

glaxosmithkline australia pty ltd - pertussis filamentous haemagglutinin, quantity: 50 microgram/ml; pertactin, quantity: 16 microgram/ml; tetanus toxoid, quantity: 80 iu/ml; pertussis toxoid, quantity: 50 microgram/ml; diphtheria toxoid, quantity: 60 iu/ml - injection, suspension - excipient ingredients: water for injections; aluminium hydroxide hydrate; sodium chloride - infanrix is indicated as fourth and fifth dose for children from 15 months of age up to and including 6 years of age who have been immunised previously with three or four doses of diphtheria, tetanus and pertussis (whole-cell) vaccine. indications as of 8th january 1997 - infanrix (dtpa) is indicated for active primary immunisation against diphtheria, tetanus and pertussis when commenced between 2 months and 12 months of age. infanrix (dtpa) is also indicated as fourth and fifth dose for children from 15 months of age up to and including 6 years of age who have been immunised previously with three or four doses of diphtheria,tetanus and pertussis (whole-cell or acellular) vaccine.

INFANRIX diphtheria toxoid / pertactin / pertussis filamentous haemagglutinin / pertussis toxoid / tetanus toxoid 0.5mL injectio Australia - English - Department of Health (Therapeutic Goods Administration)

infanrix diphtheria toxoid / pertactin / pertussis filamentous haemagglutinin / pertussis toxoid / tetanus toxoid 0.5ml injectio

glaxosmithkline australia pty ltd - pertussis filamentous haemagglutinin, quantity: 50 microgram/ml; pertactin, quantity: 16 microgram/ml; pertussis toxoid, quantity: 50 microgram/ml; tetanus toxoid, quantity: 20 lfu/ml; diphtheria toxoid, quantity: 50 lfu/ml - injection, suspension - excipient ingredients: water for injections; aluminium hydroxide hydrate; sodium chloride - infanrix is indicated as fourth and fifth dose for children from 15 months of age up to and including 6 years of age who have been immunised previously with three or four doses of diphtheria, tetanus and pertussis (whole-cell) vaccine. indications as of 8th january 1997 - infanrix (dtpa) is indicated for active primary immunisation against diphtheria, tetanus and pertussis when commenced between 2 months and 12 months of age. infanrix (dtpa) is also indicated as fourth and fifth dose for children from 15 months of age up to and including 6 years of age who have been immunised previously with three or four doses of diphtheria,tetanus and pertussis (whole-cell or acellular) vaccine.

NEISVAC-C VACCINE meningococcal group c polysaccharide conjugate vaccine suspension for injection syringe Australia - English - Department of Health (Therapeutic Goods Administration)

neisvac-c vaccine meningococcal group c polysaccharide conjugate vaccine suspension for injection syringe

pfizer australia pty ltd - tetanus toxoid, quantity: 20 microgram/ml; meningococcal polysaccharide group c, quantity: 20 microgram/ml - injection, suspension - excipient ingredients: sodium chloride; water for injections; aluminium hydroxide hydrate - neisvac-c vaccine is indicated for active immunisation of children from 8 weeks of age, adolescents and adults, for the prevention of invasive disease caused by neisseria meningitidis serogroup c.

Tetavax Suspension for Injection in pre-filled syringe, adsorbed tetanus vaccine Malta - English - Medicines Authority

tetavax suspension for injection in pre-filled syringe, adsorbed tetanus vaccine

jv healthcare limited navi buidlings, pantar road, lija, lja 2021, malta - tetanus toxoid, aluminium hydroxide, hydrated - suspension for injection - tetanus toxoid 40 iu aluminium hydroxide, hydrated 0.6 mg - vaccines

TETAVAX, suspension for injection in prefilled syringe, adsorbed tetanus vaccine. Malta - English - Medicines Authority

tetavax, suspension for injection in prefilled syringe, adsorbed tetanus vaccine.

sanofi pasteur 14 espace henry vallée , 69007 lyon, france - tetanus toxoid - suspension for injection in pre-filled syringe - tetanus toxoid - vaccines

TETANUS TOXOID ADSORBED SUSPENSION Canada - English - Health Canada

tetanus toxoid adsorbed suspension

id biomedical corporation of quebec - tetanus toxoid adsorbed - suspension - 5lf - tetanus toxoid adsorbed 5lf - toxoids

ADACEL pertussis vaccine-acellular combined with diphtheria and tetanus toxoids (adsorbed) 0.5mL injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

adacel pertussis vaccine-acellular combined with diphtheria and tetanus toxoids (adsorbed) 0.5ml injection vial

sanofi-aventis australia pty ltd - diphtheria toxoid, quantity: 2 iu; pertussis filamentous haemagglutinin, quantity: 5 microgram; pertussis toxoid, quantity: 2.5 microgram; pertussis fimbriae 2 + 3, quantity: 5 microgram; pertactin, quantity: 3 microgram; tetanus toxoid, quantity: 20 iu - injection, suspension - excipient ingredients: glutaral; formaldehyde; phenoxyethanol; water for injections; aluminium phosphate - adacel is indicated for active immunisation against tetanus, diphtheria and pertussis in persons aged 10 years and over as a booster following primary immunisation. adacel may be administered during pregnancy for prevention of pertussis in young infants via transplacental antibody transfer from the pregnant woman to the fetus.